EUVIMEDEUVIMED entdecken
Multizentrische Studie

Same‐day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony‐stimulating factor mobilization

Same-Day-Rescue-Plerixafor während der Leukapherese ist sicher und wirksam bei allogenen Spendern mit suboptimaler Antwort auf G-CSF-Mobilisierung

Yen-Michael S Hsu iD, Amy Ellsworth iD, Chong H Kim, Jeramy Davies, Hannah Erskine, Anthony Miller, Kimberly A Kasow iD, Heather E Stefanski iD, Richaele Nichiporenko, Jamie Margolis, Kathleen Burke iD, Jennifer Galloway und 11 weitere

Transfusion · 2026-11 · 66 (11) · 2313-2322

DOI: 10.1111/trf.70376 ↗

Auf einen Blick

Bei allogenen Spendern mit CD34+-Werten ≤30/μL war die same-day Gabe von Plerixafor während der Leukapherese mit höherer CD34+-Ausbeute und ohne mehr Nebenwirkungen verbunden.

Fragestellung

Welche Wirkung hat die sofortige Plerixafor-Gabe ohne Unterbrechung der Leukapherese bei G-CSF-mobilisierten allogenen Spendern mit CD34+ ≤30/μL?

Methode

Retrospektive 2-Zentren-Analyse von Daten aus 10/2023 bis 11/2025; Vergleich von G-CSF plus Plerixafor ohne Unterbrechung der Leukapherese mit G-CSF allein.

Ergebnisse

G + P: keine Zunahme von Thrombozytenverlust oder grade-2-oder-höheren gastrointestinalen/Immun-Nebenwirkungen; keine Tag-2-Sammlung nötig. In der LP-Phase etwa 5,5-fache Zunahme der medianen CD34+-Zellen/L verarbeitet/h; p < .0001.

Schlussfolgerung der Autor:innen

Same-day rescue plerixafor ohne Unterbrechung der Leukapherese führte bei allogenen Spendern mit unzureichender G-CSF-Antwort zu einer sicheren und effizienten Sammlung bei erhaltener PBSC-Produktqualität.

Kernaussagen

  • Keine Zunahme von Thrombozytenverlust oder grade-2-oder-höheren Nebenwirkungen
  • In der LP-Phase etwa 5,5-fache Zunahme der medianen CD34+-Zellen/L verarbeitet/h
  • Alle PBSC-Produkte der G + P-Gruppe erfüllten den Zielwert; 63 % der Kontrollen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transfusion, online erschienen am 01.09.2026. Verfasst von Yen-Michael S Hsu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Gift of Life Marrow Registry, Adelson-NMDP Collection Center, Boca Raton, Florida, USA. Hauptthemen laut MEDLINE: Benzylamines, Cyclams, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization. Die Arbeit nennt 30 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plerixafor (P) is a rescue mobilization agent given to improve circulating CD34+ for peripheral blood stem cell (PBSC) collection in donors with inadequate response to granulocyte colony‐stimulating factor (G‐CSF, [G]). In this study, we evaluated the impact of immediate plerixafor administration without leukapheresis interruption for the same‐day PBSC collection in G‐mobilized allogeneic donors with pre‐apheresis peripheral blood CD34+ count ≤30/μL. Study Design Retrospective analysis of two‐center data from 10/2023 to 11/2025 was conducted. The study group (G + P) received G‐CSF for 5 days and plerixafor without leukapheresis interruption ( n = 12). The control group (G, n = 24) received 5‐day G‐CSF and had similar median apheresis procedure time as study group. Outcomes were evaluated at early procedure (EP) and late procedure (LP) periods, separated by the timing of the interim PBSC product characterization.

Results

G + P donors did not experience increased platelet loss or grade 2 or greater adverse reactions in gastrointestinal and immune systems or required day‐2 collection. During the LP period, G + P group had approximately 5.5‐fold increase in median CD34+ cells/L processed/h apheresis ( p < .0001). During the LP period, while G + P group had significant gains in CD34+ yield, there was a significant loss in the control group ( p < .0087). CD34+ collection efficiency was significantly higher in G + P ( p < .0001). All PBSC products from G + P group contained ≥4.5 × 10 6 CD34+/kg recipient while only 63% of controls met this threshold ( p = .016).

Conclusions

Same‐day rescue plerixafor without leukapheresis interruption in allogeneic donors suboptimally responding to G‐CSF results in safe and efficient leukapheresis collection while preserving PBSC product quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsLeukapheresisAdultFemaleHumansMaleMiddle AgedAntigens, CD34Blood DonorsRetrospective StudiesTransplantation, Homologous

Stichwörter der Autor:innen

allogeneic donorsapheresiscellular therapycollectionmobilization

Substanzen

Antigens, CD34BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixafor

Autor:innen und Institutionen

  • Gift of Life Marrow Registry, Adelson-NMDP Collection Center, Boca Raton, Florida, USA.
  • Gift of Life Marrow Registry, Center for Cell and Gene Therapy, Boca Raton, Florida, USA.
  • Clinical Research, Gift of Life Marrow Registry, Boca Raton, Florida, USA.
  • NMDP Seattle Apheresis Collection Center, Seattle, Washington, USA.
  • NMDP, Minneapolis, Minnesota, USA.
  • Independent Researcher, San Francisco, California, USA.

ORCID-Profile: Yen-Michael S Hsu, Amy Ellsworth, Kimberly A Kasow, Heather E Stefanski, Kathleen Burke, Steven Devine, Huy P Pham

Zitieren

APA

Hsu, Y. S., Ellsworth, A., Kim, C. H., Davies, J., Erskine, H., Miller, A., Kasow, K. A., Stefanski, H. E., Nichiporenko, R., Margolis, J., Burke, K., Galloway, J., Knutson, L., Ondricek, S., Khan, F., Guidry-Groves, H., Feinberg, J., Fisher, J., Johnson, H., …, & Pham, H. P. (2026). Same‐day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony‐stimulating factor mobilization. Transfusion, 66(11), 2313-2322. https://doi.org/10.1111/trf.70376

Vancouver

Hsu YS, Ellsworth A, Kim CH, Davies J, Erskine H, Miller A, et al. Same‐day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony‐stimulating factor mobilization. Transfusion. 2026;66(11):2313-2322. doi:10.1111/trf.70376

BibTeX
@article{Hsu2026,
  author = {Hsu, Yen-Michael S and Ellsworth, Amy and Kim, Chong H and Davies, Jeramy and Erskine, Hannah and Miller, Anthony and Kasow, Kimberly A and Stefanski, Heather E and Nichiporenko, Richaele and Margolis, Jamie and Burke, Kathleen and Galloway, Jennifer and Knutson, Lisa and Ondricek, Sara and Khan, Farida and Guidry-Groves, Hope and Feinberg, Jay and Fisher, Jennifer and Johnson, Heidi and Retterath, Lori and Lenes, Bruce A and Devine, Steven and Pham, Huy P},
  title = {Same‐day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony‐stimulating factor mobilization},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {11},
  pages = {2313--2322},
  doi = {10.1111/trf.70376}
}
Kostenlos starten →